Modified Release Drug Delivery Systems: Impact on Pharmacokinetics, Therapeutic Efficacy and Patient Compliance
DOI:
https://doi.org/10.31580/6p346f86Keywords:
Adherence, Bioavailability, Chronic disease management, Controlled release, Extended-release formulations, Modified release drug delivery systems, Patient compliance, Pharmacokinetics, Precision medicine, Therapeutic efficacyAbstract
Modified Release Drug Delivery Systems (MRDDS) are significant advancements in pharmaceutical formulation, enhancing pharmacokinetic modulation and therapeutic efficacy while improving patient compliance. This review assesses literature from 2016 to 2026, highlighting that MRDDS modify drug absorption by delaying Tmax, lowering Cmax, and maintaining therapeutic drug levels, leading to better therapeutic predictability and reduced toxicity. Especially beneficial for chronic conditions like hypertension and diabetes, MRDDS support once-daily dosing, improving adherence and patient satisfaction. Although challenges in manufacturing and costs persist, innovations in nanotechnology and personalized medicine are setting the stage for enhanced controlled drug delivery, positioning MRDDS as a key strategy for optimizing long-term pharmacotherapy and improving patient-centered care.
References
1. Drapińska P, Skulmowska-Polok K, Chałupka J, Sikora A. Sustained-Release Oral Delivery of NSAIDs and Acetaminophen: Advances and Recent Formulation Strategies—A Systematic Review. Pharmaceutics. 2025;17(10):1264.
2. Atre P, Rizvi S. Advances in Oral Solid Drug Delivery Systems: Quality by Design Approach in Development of Controlled Release Tablets. BioChem. 2025;5(1):12-31.
3. Prajapat P, Agrawal D, Bhaduka G. A brief overview of sustained released drug delivery system. Journal of Applied Pharmaceutical Research. 2022;10(2):1-9.
4. Wheless J, Phelps S. A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.2018;23(4):277-292.
5. Park H, Otte A, Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of controlled release : official journal of the Controlled Release Society. 2021;340(1):125-132.
6. Pund A, Mundada A, Magar M, Kadam A. Recent Patents on Modified Release Oral Dosage Forms. Journal of Drug Delivery and Therapeutics. 2021;11(4-S):161-167.
7. Upadhyay P, K., Chaudhary P, Upadhyay S. A Review on Formulation and Evaluation Approaches for Fast Release Tablet. Mathews Journal of Pharmaceutical Science. 2023, 7(2):23-31.
8. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021;26(19):5905.
9. Gidal B, Ferry J, Reyderman L, Pina-Garza J. Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for clinicians. Epilepsy & Behavior. 2021;120(1):108011.
10. Jain R, Tiwari R, Dubey R, Tiwari A, Shukla A. Controlled drug release rate and contemporary issues in oral drug delivery formulations. Advance Pharmaceutical Journal. 2021;6(2):45-53.
11. Baryakova T, Pogostin B, Langer R, McHugh K. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nature Reviews Drug Discovery. 2023;22(5):387-409.
12. Jangid AK, Dev R, Sharma S, Bhatnagar P. Revolutionizing therapeutics: advances, challe- nges, and future horizons in controlled release drug delivery systems. Current Research in Pharmaceutical Sciences. 2025;15(1):10-24.
13. Late S, Gandhi B. A Review on Modified Release Dosage Form. International Journal of Advanced Research in Science, Communication and Technology. 2023;3(1):412-421.
14. Nandy B, Gupta A. A brief review on recent advances of extended release technology employed to design the oral dosage forms. 2017;1(2):78-85.
15. Milián-Guimerá C, McCabe R, Thamdrup L, Ghavami M, Boisen A. Smart pills and drug delivery devices enabling next generation oral dosage forms. Journal of controlled release : official journal of the Controlled Release Society. 2023;362(1):358-371.
16. Shahrbabak SM, Jalali SM, Fathabadi MF, Tayebi-Khorrami V, Amirinejad M, Forootan S, Saberifar M, Fadaei MR, Najafi Z, Askari V. Modified alginates for precision drug delivery: Advances in controlled-release and targeting systems. International Journal of Pharmaceutics: X. 2025;10(1):100290.
17. Hye T, Moinuddin S, Sarkar T, Nguyen T, Saha D, Ahsan F. An evolving perspective on novel modified release drug delivery systems for inhalational therapy. Expert Opinion on Drug Delivery. 2023, 20(3):335-348.
18. Mahajan KR, Gorle AP, Khalane VS. Overview on pulsatile drug delivery system. International Journal of Science and Research Archive. 2022;5(2):114-123.
19. Deshmukh J. A review on: Pulsatile drug delivery system. 2020;11(3):91-99.
20. Lucas CJ, Galettis P, Schneider JJBjocp. The pharmacokinetics and the pharmacodynamics of cannabinoids. 2018;84(11):2477-82.
21. Jarrett AM, Faghihi D, Hormuth DA, Lima EA, Virostko J, Biros G, Patt D, Yankeelov TEJJocm. Optimal control theory for personalized therapeutic regimens in oncology: Background, history, challenges, and opportunities. 2020;9(5):1314.
22. Gondkar S, Lankesh P, Saudagar R. An Overview on Sustain Release Matrix Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology. 2016;8(3):154-160.
23. Wang S, Liu R, Fu Y, Kao J. Release mechanisms and applications of drug delivery systems for extended-release. Expert Opinion on Drug Delivery. 2020;17(9):1289-1304.
24. Narayan R, Nayak UY, Raichur AM, Garg SJP. Mesoporous silica nanoparticles: A comprehensive review on synthesis and recent advances. 2018;10(3):118.
25. Sune P, Jumde K, Hatwar P, Bakal R, Korde A. Advances in oral controlled release drug delivery systems. GSC Biological and Pharmaceutical Sciences. 2024;26(2):145-156.
26. Chen G, Kang W, Li W, Chen S, Gao Y. Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies. Theranostics. 2022;12(3):1419-1439.
27. Gaydhane M, Sharma C, Majumdar S. Electrospun nanofibres in drug delivery: advances in controlled release strategies. RSC Advances. 2023;13(11):7312-7328.
28. Leucuta S. Drug delivery systems with modified release for systemic and biophase bioavailability. Current clinical pharmacology. 2012;7(4):282-317.
29. Qiu Y, Lee P. Rational Design of Oral Modified-Release Drug Delivery Systems. 2017, 3(1):519-554..
30. Bermejo M, Sánchez-Dengra B, González-Álvarez M, González-Álvarez I. Oral controlled release dosage forms: dissolution versus diffusion. Expert Opinion on Drug Delivery. 2020;17(6):791-803.
31. Varum F, Merchant H, Basit A. Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption. International journal of pharmaceutics. 2010;395(1-2):26-36.
32. Sood A, Panchagnula R. Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index. International journal of pharmaceutics. 2003;261(1-2):27-41.
33. Hashida M. Role of pharmacokinetic consideration for the development of drug delivery systems: A historical overview. Advanced drug delivery reviews. 2020;157(1):4-17.
34. Perumal O, Haywood A, Glass B, Ho P. Pharmacokinetics and biopharmaceutics. 2011;2(1):41-86.
35. Ritschel W. Biopharmaceutic and pharmacokinetic aspects in the design of controlled release peroral drug delivery systems. Drug Development and Industrial Pharmacy. 1989;15(6-7):1073-1103.
36. Murugesan S, Gowramma B, Lakshmanan K, Karri VVSR, Radhakrishnan A. Oral modified drug release solid dosage form with special reference to design; An overview. Current drug research reviews. 2019;11(2):88-101.
37. Laracuente M-L, Yu M, McHugh K. Zero-order drug delivery: State of the art and future prospects. Journal of controlled release : official journal of the Controlled Release Society. 2020;327(1):86-103.
38. Cohen S, Greenberg J, Harnett J, Madsen A, Smith T, Gruben D, Zhang R, Lukić T, Woolcott J, Dandreo K, Litman H, Blachley T, Lenihan A, Chen C, Rivas J, Dougados M. Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis. Advances in Therapy. 2020;38(1):226-248.
39. Gujral G, Kapoor D, Jaimini M. An updated review on modified release tablets. Journal of Drug Delivery and Therapeutics. 2018;8(4):389-397.
40. Stewart P. Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice? Journal of the Endocrine Society. 2019;3(6):1150-1153.
41. Vlachou M, Kikionis S, Siamidi A, Tragou K, Ioannou E, Roussis V, Tsotinis A. Modified In Vitro Release of Melatonin Loaded in Nanofibrous Electrospun Mats Incorporated Into Monolayered and Three-Layered Tablets. Journal of pharmaceutical sciences. 2019;108(2):970-976.
42. Tremblay S, Alloway R. Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. The AAPS Journal. 2017, 19(5):1332-1347.
43. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021;26(19):5905.
44. Yan VKC, Ju C, MacDonald T, Mackenzie I, Flynn R, Williams B, Chen Y, Chan E, George J, Wei L. Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study. BMJ Medicine. 2025;4(1):e000321.
45. Brewster P, Bari SMI, Walker G, Werfel T. Current and Future Directions of Drug Delivery for the Treatment of Mental Illnesses. Advanced drug delivery reviews. 2023;199(1):114824.
46. Kim Y, Park K, Kim MS. Recent advances in polymer-based drug delivery systems for atopic dermatitis: enhancing therapeutic efficacy and outcomes. Materials Today Bio. 2025;35(1):101344.
47. Heng P. Controlled release drug delivery systems. Pharmaceutical Development and Technology. 2018;23(9):833-834.
48. Ghormade J, Yadav S, Burakle P, Raut A. The role of matrix tablet in controlled release drug delivery system. GSC Biological and Pharmaceutical Sciences. 2023;24(2):112-121.
49. Shekhar S, Kumar A, Rana V, Kumar R, Mittal C, Tariyal K. Recent Approaches of Matrix Release Tablet in NDDS System. Journal for Research in Applied Sciences and Biotechnology. 2023, 2(3):45-56.
50. Anjali B, Komal T. Sustained release matrix drug delivery system: an overview. International Journal of Pharmaceutical Sciences and Medicine. 2021;6(8):12-25.
51. Maderuelo C, Zarzuelo A, Lanao J. Critical factors in the release of drugs from sustained release hydrophilic matrices. Journal of controlled release : official journal of the Controlled Release Society. 2011;154(1):2-19.
52. Bansode A, Sarvanan K. REVIEW ON NOVEL OSMOTIC DRUG DELIVERY SYSTEM. Journal of Drug Delivery and Therapeutics. 2018;8(3):311-319.
53. Abdul S, Poddar S. A flexible technology for modified release of drugs: multi layered tablets. Journal of controlled release : official journal of the Controlled Release Society. 2004;97(3):393-405.
54. Keraliya R, Patel C, Patel P, Keraliya V, Soni T, Patel R, Patel a. Osmotic Drug Delivery System as a Part of Modified Release Dosage Form. ISRN Pharmaceutics. 2012;2012(1):528079.
55. Almoshari Y. Osmotic Pump Drug Delivery Systems—A Comprehensive Review. Pharmaceuticals. 2022;15(11):1430.
56. Gupta B, Thakur N, Jain N, Banweer J, Jain S. Osmotically controlled drug delivery system with associated drugs. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2010;13(4):571-588.
57. Yoshida T, Kojima H. Oral Drug Delivery Systems Applied to Launched Products: Value for the Patients and Industrial Considerations. Molecular pharmaceutics. 2023;20(8):3789-3804.
58. Kamaly N, Yameen B, Wu J, Farokhzad O. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chemical reviews. 2016;116(4):2602-2663.
59. Malekjani N, Jafari S. Modeling the release of food bioactive ingredients from carriers/nanocarriers by the empirical, semiempirical, and mechanistic models. Comprehensive reviews in food science and food safety. 2021;20 (1):3-47.
60. Bayer I. Controlled Drug Release from Nanoengineered Polysaccharides. Pharmaceutics. 202;15(4):1122.
61. Gioumouxouzis C, Tzimtzimis E, Katsamenis O, Dourou A, Markopoulou C, Bouropoulos N, Tzetzis D, Fatouros D. Fabrication of an osmotic 3D printed solid dosage form for controlled release of active pharmaceutical ingredients. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2019;140(1):105176.
62. Ahmed S, Alhareth K, Mignet N. Advancement in Nanogel formulations provides controlled drug release. International journal of pharmaceutics. 2020;585(1):119435.
63. Haseeb M, Hussain M, Bashir S, Ashraf M, Ahmad N. Evaluation of superabsorbent linseed-polysaccharides as a novel stimuli-responsive oral sustained release drug delivery system. Drug Development and Industrial Pharmacy. 201;43(3):409-420.
64. Rehmat S, Rizvi N, Khan S, Ghaffar A, Islam A, Khan R, Mehmood A, Butt H, Rizwan M. Novel Stimuli-Responsive Pectin-PVP-Functionalized Clay Based Smart Hydrogels for Drug Delivery and Controlled Release Application. 2022;14(9):1822.
65. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based nanoparticles. Heliyon. 2021;7(8):e07747.
66. Sandersleben HU-V, Mayer A, Ruhmann M, Dangel O, Schütz H. Pharmacokinetics of a Modified-Release Dexamphetamine Sulfate Formulation Following Single and Multiple Dosing in Healthy Adults: Comparative Bioavailability with Immediate-Release Dexamphetamine Sulfate, between Strengths, Assessment of Food and Meal Composition Effects. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology. 2023;11(1):132-142.
67. Dangi A, Sharma K. Development and Characterization of Modified Release Dosage Form Utilizing Semaglutide. International Journal of Drug Delivery Technology. 2025;15(1):88-94.
68. Ojsteršek T, Hudovornik G, Vrečer FJP. Influence of Selected Hypromellose Functionality-Related Characteristics and Soluble/Insoluble Filler Ratio on Carvedilol Release from Matrix Tablets. 2025;17(10):1358.
69. Wilkins CA, Hamman H, Hamman JH, Steenekamp JHJP. Fixed-dose combination formulations in solid oral drug therapy: advantages, limitations, and design features. 2024;16(2):178.
70. Garg R, Kaur S, Ritika SK, NAINA HVJIJAP. A complete and updated review on various types of drug delivery systems. 2020;12(4):11-23.
71. Almoshari YJP. Osmotic pump drug delivery systems—a comprehensive review. 2022;15(11):1430.
72. Askarizadeh M, Esfandiari N, Honarvar B, Sajadian SA, Azdarpour AJCR. Kinetic modeling to explain the release of medicine from drug delivery systems. 2023;10(6):1006-49.
73. Nadia A, Holly L, Amanda P, Brian C, Kimberly R, Timothy J, Salaheldin H, Kaushalkumar D. Retrospective analysis of the biopharmaceutics characteristics of solid oral Modified-Release drug products in approved US FDA NDAs designated as Extended-Release or Delayed-Release formulations. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2023;191(1):114-126.
74. Hsieh N-H, Bois F, Tsakalozou E, Ni Z, Yoon M, Sun W, Klein M, Reisfeld B, Chiu W. A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms. Journal of Pharmacokinetics and Pharmacodynamics. 2021;48(6):893-908.
75. Spyker D, Dart R, Yip L, Reynolds K, Brittain S, Yarema M. Population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations. Clinical Toxicology. 2022;60(11):1113-1121.
76. Sidgiddi S, Gautam A. Comparative Bioavailability of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) Vs. Minocycline Hydrochloride Extended Release 105-mg tablets After a Single Oral Dose: A Randomized, 3-way Crossover Study. SKIN The Journal of Cutaneous Medicine. 2023; 7(2):s114.
77. Stillhart C, Vučićević K, Augustijns P, Basit A, Batchelor H, Flanagan T, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, Madla C, Matthys C, Miljuš G, Mooij M, Parrott N, Ungell A, De Wildt S, Orlu M, Klein S, Müllertz A. Impact of gastrointestinal physiology on drug absorption in special populations - An UNGAP review. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2020;147(1):105280.
78. Subhani S, Lukacova V, Kim C, Rodríguez-Vera L, Muñiz P, Rodriguez M, Cristofoletti R, Van Os S, Suárez E, Schmidt S, Vozmediano V. Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions. Pharmaceutics. 2023;15(5):1390.
79. Askarizadeh M, Esfandiari N, Honarvar B, Sajadian S, Azdarpour A. Kinetic Modeling to Explain the Release of Medicine from Drug Delivery Systems. ChemBioEng Reviews. 2023, 10(6):1006-1049.
80. Hirsch I, Juneja R, Beals J, Antalis C, Wright E. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocrine Reviews. 2020;41(5):733-755.
81. Zhang J, Wei X, Liu W, Wang Y, Kahkoska A, Zhou X, Zheng H, Zhang W, Sheng T, Zhang Y, Liu Y, Ji K, Xu Y, Zhang P, Xu J, Buse J, Wang J, Gu Z. Week-long norm glycaemia in diabetic mice and minipigs via a subcutaneous dose of a glucose-responsive insulin complex. Nature Biomedical Engineering. 2023;7(7):877-888.
82. Amponsah S, Yeboah S, Kukuia K, N'Guessan BB, Adi-Dako O. A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine. Advances in Pharmacological and Pharmaceutical Sciences. 2021;2021(1):6692301.
83. Saleh-Bey-Kinj Z, Heller Y, Socratous G, Christodoulou P. 3D Printing in Oral Drug Delivery: Technologies, Clinical Applications and Future Perspectives in Precision Medicine. Pharmaceuticals. 2025;18(2):142.
84. Peng Z, Meng F, Deng Q, Huang Y, Mao D, Long Y, Yan W, Peng J, Wang X, Liu N. Advances in drug delivery systems for the management of gout and hyperuricemia. Frontiers in Pharmacology. 2025; 16(1):104230.
85. Siddiqui S, Sharma K, Handa V, Grover P. Chronotherapeutic Drug Delivery Systems: An approach to synchronize drug concentrations to circadian rhythms in disease state. Journal of emerging technologies and innovative research. 2019;6(5):344-353.
86. Wadi A, Pandey P, Sheikh T, Elkanayati R, Cherif A, Chakka J, Maniruzzaman M. Programmable delayed-release container system (PDRCS) for chronotherapeutic delivery: application in personalized treatment for Addison's disease. International journal of pharmaceutics. 2025;672(1):126245.
87. Chen Q, Yang Z, Liu H, Man J, Oladejo A, Ibrahim S, Wang S-X, Hao B-C. Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development. Pharmaceutics. 2024;16(4):450.
88. Yang J, Zeng H, Luo Y, Chen Y, Wang M, Wu C, Hu P. Recent Applications of PLGA in Drug Delivery Systems. Polymers. 2024;16(6):812.
89. Liu S, Deng T, Cheng H, Lu J, Wu J. Advances in Transdermal Drug Delivery Systems and Clinical Applications in Inflammatory Skin Diseases. Pharmaceutics. 2025;17(1):102.
90. Sahu GK. A Review on Role of Sustained Release Tablets in Improving Patient Compliance and Therapeutic Outcomes. Interantional journal of scientific research in engineering and management. 2024;8(3):214-225.
91. Toti L, Manzia T, Blasi F, Lenci I, Baiocchi L, Toschi N, Tisone G. Renal Function, Adherence and Quality of Life Improvement After Conversion From Immediate to Prolonged-Release Tacrolimus in Liver Transplantation: Prospective Ten-Year Follow-Up Study. Transplant International. 2022;35(1):10312.
92. Magar KT, Boucetta H, Zhao Z, Xu Y, Liu Z, He W. Injectable long-acting formulations (ILAFs) and manufacturing techniques. Expert Opinion on Drug Delivery. 2024;21(7):881-904.
93. Altreuter D, Kirtane A, Grant T, Kruger C, Traverso G, Bellinger A. Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form. Expert Opinion on Drug Delivery. 2018;15(12):1189-1198.
94. Romley J, Xie Z, Chiou T, Goldman D, Peters A. Extended-Release Formulation and Medication Adherence. Journal of General Internal Medicine. 2019;35(2):354-356.
95. Molteni L, Marelli G, Castagna G, Brambilla L, Acerbis M, Alberghina F, Carpani A, Chiavenna E, Ferlini MG, Impellizzeri C, Paredi R, Rigamonti A, Rivolta G, Disoteo O. Improving Type 2 Diabetes Care with Extended-Release Metformin: Real-Life Insights from a Physician Educational Program. Endocrine, Metabolic & Immune Disorders Drug Targets. 2024;24(12):1422-1430.
96. Vrettos N-N, Roberts C, Zhu Z. Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications. Pharmaceutics. 2021;13(10):1677.
97. Yadav AS, Bhatt S, Verma K, Shukla D, Gupta D. Therapeutic Implication of the Transdermal Patches in Treatment of the Chronic Diseases. Journal of Drug Discovery and Health Sciences. 2025, 5(1):44-53.
98. Homayun B, Lin X, Choi H-J. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics. 2019;11(3):129.
99. Rajan J, Rajan V, Kaur B. Alcohol induced dose dumping in modified release formulations in vivo and in vitro studies: Comprehensive review. International journal of health sciences. 2022;6(S3):5321-5335.
100. Asgarzadeh F, Gray A, Hughes K, Hebestreit J-P, Rosiaux Y, Yunis M, Faham A. Regulatory Considerations for Alcohol-Induced Dose Dumping of Oral Modified-Release Formulations. 2015;39(10):44-52.
101. Jedinger N, Khinast J, Roblegg E. The design of controlled-release formulations resistant to alcohol-induced dose dumping--a review. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2014;87(2):217-226.
102. Langer C, Diaz D, Van Alstine L, Bandi N, Fitzgerald S, Colgan S. Analysis of the Regulatory Divergence of Comparative Dissolution Requirements for Post-Approval Manufacturing Changes of Modified Release Solid Oral Dosage Forms. The AAPS Journal. 2019;22(1):14.
103. Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. The AAPS Journal. 2015;17(6):1327-1340.
104. Raijada D, Wac K, Greisen E, Rantanen J, Genina N. Integration of personalized drug delivery systems into digital health. Advanced drug delivery reviews. 2021;176(1):113857.
105. Ezike T, Okpala US, Onoja UL, Nwike C, Ezeako E, Okpara OJ, Okoroafor CC, Eze S, Kalu OL, Odoh EC, Nwadike UG, Ogbodo J, Umeh B, Ossai E, Nwanguma B. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9(6):e16582.
106. Myung N, Jin S, Cho H, Kang H. User-designed device with programmable release profile for localized treatment. Journal of controlled release : official journal of the Controlled Release Society. 2022; 348(1):112-121.
107. Hauck M, Dittmann J, Zeller‐Plumhoff B, Madurawala R, Hellmold D, Kubelt C, Synowitz M, Held-Feindt J, Adelung R, Wulfinghoff S, Schütt F. Fabrication and Modelling of a Reservoir-Based Drug Delivery System for Customizable Release. Pharmaceutics. 2022;14(9):1854.
108. Zou H, Banerjee P, Leung S, Yan X. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. Frontiers in Pharmacology. 2020;11(1):997.
109. De Souza FP, Zimmermann ES, Silva RTC, Borges LN, Nova MV, De Souza Lima MM, Diniz A. Model-Informed Drug Development of Gastroretentive Release Systems for Sildenafil Citrate. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2022, 179(1):12-24.
110. Subhani S, Kim C, Muñiz P, Rodriguez M, Van Os S, Suárez E, Cristofoletti R, Schmidt S, Vozmediano V. Application of Physiologically Based Absorption and Pharmacokinetic Modeling in the development process of oral modified release generic products. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2022;177(1):45-58.
111. Kalhapure R, Palekar S, Patel K, Monpara J. Nanocrystals for controlled delivery: state of the art and approved drug products. Expert Opinion on Drug Delivery. 2022;19(10):1303-1316.
112. Zhang CQ, Li H, Wan Y, Bai X, Gan L, Wang J, Sun H-B. Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials. Frontiers in Pharmacology. 2022;13(1):901142.
113. Compton W, Volkow N. Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes. JAMA network open. 2021;4(5):e219711.
114. Wang X, Li C, Wang Y, Chen H, Zhang X, Luo C, Zhou W, Li L, Teng L, Yu H, Wang J. Smart drug delivery systems for precise cancer therapy. Acta Pharmaceutica Sinica B. 2022;12(11):4098-4121.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Pak-Euro Journal of Medical and Life Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
